eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2020
vol. 37
 
Share:
Share:
more
 
 
abstract:
Original paper

Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients

Dominika Wcisło-Dziadecka
1
,
Beniamin Grabarek
2, 3, 4
,
Celina Kruszniewska-Rajs
2
,
Andrzej S. Swinarew
5, 6
,
Krzysztof Jasik
7
,
Beata Rozwadowska
8, 9
,
Agata Krawczyk
10

1.
Department of Cosmetology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
2.
Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
3.
Department of Histology, Cytophysiology and Embryology in Zabrze, Faculty of Medicine in Zabrze, University of Technology in Katowice, Poland
4.
District Hospital, Chrzanow, Poland
5.
Faculty of Science and Technology in Chorzow, University of Silesia in Katowice, Poland
6.
Department of Swimming and Water Rescue, Institute of Sport Science, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
7.
Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
8.
Provincial Sanitary and Epidemiological Station, Katowice, Poland
9.
Silesian Medical College in Katowice, Poland
10.
Department of Nutrigenomics and Bromatology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Poland
Adv Dermatol Allergol 2020; XXXVII (5): 736-745
Online publish date: 2020/11/07
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Through interaction with receptors TNFR1 and TNFR2, TNF-a activates a signal path, which exacerbates an inflammatory process, constituting an inseparable element of psoriasis.

Aim
To evaluate changes in the expression of TNF-a, TNFR1, TNFR2 during the 4-year-long adalimumab therapy in psoriatic patients, searching for the correlation between molecular and clinical markers. In addition, the role of miRNAs was analysed.

Material and methods
Whole blood and serum samples of psoriatic patients treated with adalimumab constituted material for the study. Changes in the expression of TNF-a and its receptors were evaluated with the use of the RTqPCR method and MALDI ToF mass spectroscopy, PASI, BSA, DAS28 indexes were used for the clinical analysis of the patients, while the role of miRNA molecules was determined basing on microrna.org database

Results
Different TNF-a expression patterns were determined in patients with observed resistance to the medicine. We found that there is a correlation between the molecular markers of an inflammatory process and the clinical indexes. The bioinformatic analysis indicates the potential role of miRNAs in the regulation of expression of the analysed genes. Changes in the profile of TNF-a during adalimumab therapy are significantly determined by the individual variability and susceptibility to the biological medicine or its loss.

Conclusions
TNF-a seems to be a useful marker to evaluate the efficacy of therapy and occurring resistance to the medicine. A complex mechanism for the regulation of the analysed gene expression was underlined, which involved the potential role of miRNAs.

keywords:

tumor necrosis factor a, treatment personalisation, miRNA, anti-TNF therapy, psoriasis

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe